Approval · Notice of Compliance 26254 · 2024
BENLYSTA: Notice of Compliance 26254
Issued March 15, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26254
- Date
- March 15, 2024
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change to the drug product manufacturing process
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BENLYSTA | Not yet assigned | — |
Medicinal ingredients
- BELIMUMAB 200 MG per SYR